Relevant bibliographies by topics / B 20.5 UL 2013 G163

Contents

  1. Journal articles

Academic literature on the topic 'B 20.5 UL 2013 G163'

Author: Grafiati
Published: 4 June 2021
Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'B 20.5 UL 2013 G163.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "B 20.5 UL 2013 G163"

1

Roesch, Erin Elizabeth, and Catherine Broome. "Complement Blockade with C1 Esterase Inhibitor in Refractory Immune Thrombocytopenia." Blood 126, no. 23 (2015): 2253. http://dx.doi.org/10.1182/blood.v126.23.2253.2253.

Full text
Abstract:
Immune thrombocytopenia (ITP) is an acquired thrombocytopenia due to autoantibody-mediated destruction of platelets. Multiple therapies targeting antibody production, the reticuloendothelial system and platelet production are used to treat ITP, including glucocorticoids, intravenous immune globulin (IVIG), Rituximab, splenectomy and thrombopoietin-receptor agonists. The response to therapy is heterogeneous, supporting the concept that multiple mechanisms are ultimately responsible for thrombocytopenia. In vitro complement fixation assays have shown that serum obtained from 50% of patients with
APA, Harvard, Vancouver, ISO, and other styles
2

Panch, Sandhya R., Yu Ying Yau, Courtney Fitzhugh, et al. "Hematopoietic Progenitor Cell Mobilization In Response To G-CSF Is More Robust In Healthy African American Compared To Caucasian Donors." Blood 122, no. 21 (2013): 696. http://dx.doi.org/10.1182/blood.v122.21.696.696.

Full text
Abstract:
Abstract Hematopoietic progenitor cells (HPCs) collected by apheresis of G-CSF-stimulated donors have surpassed bone marrow as the predominant graft source for hematopoietic stem cell transplantation in adults. Among healthy allogeneic donors, demographic characteristics (age, sex, and BMI) and baseline hematologic parameters have been shown to affect HPC mobilization, leading to significant variability in peak levels of CD34 cell egress into the blood and in quantity of CD34 cells harvested by apheresis. Racial differences in G-CSF-mediated HPC mobilization are less well characterized. Benign
APA, Harvard, Vancouver, ISO, and other styles
3

Mocikova, Heidi, Magdalena Klanova, Martin Spacek, et al. "Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid." Blood 124, no. 21 (2014): 5412. http://dx.doi.org/10.1182/blood.v124.21.5412.5412.

Full text
Abstract:
Abstract Introduction: Currently, there is no consensus regarding diagnosis and treatment of occult lymphomatous menigeal involvement of cerebrospinal fluid (CSF) in patients with systemic non-Hodgkin lymphomas (NHL), especially in patients with minimal number of clonal cells detected by flow cytometry (FCM) or by cytology. Aim of the study: To describe a cohort of patients with occult lymphomatous involvement in cerebrospinal fluid including the diagnostic methods as well as management. Patients and methods: CSF at diagnosis of B-NHL was examined by FCM, cytology, biochemistry and microRNA an
APA, Harvard, Vancouver, ISO, and other styles
4

Castillo, Jorge J., James N. Butera, Eric S. Winer, Frederick Lansigan, Kayla Rosati, and Howard Safran. "Combination Of Ofatumumab and Bortezomib In Patients With Indolent B-Cell Lymphomas Who Relapsed >6 Months After Rituximab-Containing Regimen: A Brown University Oncology Research Group Phase II Study." Blood 122, no. 21 (2013): 5121. http://dx.doi.org/10.1182/blood.v122.21.5121.5121.

Full text
Abstract:
Abstract Introduction Based on the activity of ofatumumab in patients with indolent B-cell non-Hodgkin lymphoma (NHL) and the potential synergistic effect of bortezomib in combination with anti-CD20 antibody therapy, a phase II study to investigate the effect of the combination of ofatumumab and bortezomib in patients with relapsed indolent B-cell NHL who relapsed >6 months after receiving a rituximab-containing regimen was initiated. Methods Patients 18 years or older with a pathologically confirmed low-grade B-cell NHL who relapsed >6 months after a rituximab-containing regimen were in
APA, Harvard, Vancouver, ISO, and other styles
5

Chang, Julie E., Vaishalee P. Kenkre, Christopher D. Fletcher, et al. "Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma." Blood 134, Supplement_1 (2019): 5470. http://dx.doi.org/10.1182/blood-2019-124489.

Full text
Abstract:
Introduction: Chronic lymphocytic leukemia (CLL) is incurable with standard therapy. With first-line chemotherapy, some patients (pts) may achieve durable remissions of many months/years. Lenalidomide (LEN) has improved progression-free survival (PFS) when given as maintenance (MNT) therapy after front-line chemotherapy (CALGB10404, CLLM1). The combination of LEN + rituximab (LR) has activity in relapsed CLL, hypothesizing benefit as MNT therapy after first-line chemotherapy. Methods: Adult pts ≥18 years with previously untreated CLL received induction bendamustine (B) 90 mg/m2 IV days 1 &
APA, Harvard, Vancouver, ISO, and other styles
6

Baltathakis, Ioannis, Fotios Panitsas, Anna Komitopoulou, et al. "Double Umbilical Cord Blood Transplantation Offers Stable Donor Engraftment and The Prospect Of Cure In Adult Patients With High-Risk Hematologic Malignancies." Blood 122, no. 21 (2013): 5516. http://dx.doi.org/10.1182/blood.v122.21.5516.5516.

Full text
Abstract:
Abstract Allogeneic stem cell transplantation (allo-SCT) remains the main therapeutic option for patients with high-risk hematologic malignancies, albeit with the requirement of a properly matched and timely available donor. Dual-unit umbilical cord blood transplantation (dUCBT) has become an alternative modality, which offers immediate access to allo-SCT for most adult patients who lack an appropriate volunteer donor. We retrospectively analyzed the outcomes of consecutive dUCBT procedures that were undertaken by our center over a seven-year period, with focus on factors affecting engraftment
APA, Harvard, Vancouver, ISO, and other styles
7

Chari, Ajai, Hearn Jay Cho, Samir Parekh, et al. "A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma." Blood 128, no. 22 (2016): 4520. http://dx.doi.org/10.1182/blood.v128.22.4520.4520.

Full text
Abstract:
Abstract Background A treatment option for patients with relapsed/refractory multiple myeloma (RRMM) is pomalidomide(pom) and dexamethasone (dex), with an overall response rate (ORR) of 33% and median progression free survival (PFS) of 4.2 months. Adding the alkylatingagent cyclophosphamide(Cy) to pom and steroids improves ORR and PFS. Baz et al (Blood, 26 May 2016) combined daily pom with weekly dosing ofCy anddex (PCD), with an ORR of 64.7% and a median PFS of 9.5 months, although grade 3/4 neutropenia increased from 31% to 52%. In our experience, compared to weekly Cy, low dose daily oral C
APA, Harvard, Vancouver, ISO, and other styles
8

Sun, Weili, Jemily Malvar, Richard Sposto, et al. "Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium." Blood 126, no. 23 (2015): 3760. http://dx.doi.org/10.1182/blood.v126.23.3760.3760.

Full text
Abstract:
Abstract Introduction Remission induction rates after a second or greater relapse is a critical endpoint in phase II trials of childhood acute lymphoblastic leukemia (ALL). A robust benchmark is crucial for identification of novel multi-agent regimens worthy of further study. The Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium previously reported the response rates of children with multiply relapsed and refractory (R/R) ALL treated between 1995 and 2004, which provided a benchmark for clinical trials. To define more recent treatment patterns and test the robustness of
APA, Harvard, Vancouver, ISO, and other styles
9

Grosso, Dolores, Onder Alpdogan, Matthew Carabasi, et al. "2 Step Myeloablative Haploidentical Transplant (HI MA HSCT) in Intermediate and High-Risk Patients-Changing the Timing of the 2 Step Approach." Blood 132, Supplement 1 (2018): 4661. http://dx.doi.org/10.1182/blood-2018-99-110815.

Full text
Abstract:
Abstract Mortality from relapsed disease remains a significant barrier to long term survival (OS) after HI HSCT despite presumed heightened alloreactivity from the mismatched graft. The Jefferson group uses a 2 step approach to HI HSCT where patients are typically conditioned with 12 Gy total body irradiation (TBI) in 8 fractions of 1.5 Gy over 4 days, immediately followed by an infusion of 2 x 108/kg donor CD3+ cells (DLI). After 2 rest days, cyclophosphamide (CY) 60 mg/kg daily x 2 is given for bidirectional tolerization, followed a day later by a CD34 selected stem cell infusion. In an atte
APA, Harvard, Vancouver, ISO, and other styles
10

Kohla, Samah, Sarah Elkourashy, Feryal Abbas, Susanna Jane Akiki, and Mohamed A. Yassin. "Chronic Myelomonocytic Leukemia in Qatar, Single Institute Experience." Blood 136, Supplement 1 (2020): 38. http://dx.doi.org/10.1182/blood-2020-134871.

Full text
Abstract:
Background Chronic myelomonocytic leukemia (CMML) is a rare de novo clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). The diagnosis is challenging and carrying risk for leukemic transformation. The median age at CMML diagnosis is ~71-73 years, with a male preponderance. According to the 2016 World Health Organization (WHO) classification of myeloid neoplasms, CMML is characterized by the presence of sustained (>3 months) peripheral blood (PB) monocytosis (≥1 × 109/L; monocytes ≥10% of white blood
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography